Abstract：【Objective】To investigate the clinical efficacy and side effects of epirubicin, oxaliplatin and capecitabine in the treatment of advanced gastric cancer.【Methods】Eighty cases of patients with gastric cancer treated in our hospital after first-line treatment with poor results and progressive disease were given with second-line treatment.The patients were divided into group A and group B according to the different methods of medication, the Group A was given epirubicin + oxaliplatin + capecitabine (mEXO) treatment, the group B was given irinotecan + 5- fluorouracil + leucovorin (FOLFIRI) treatment, the efficacy and toxicity of two groups were compared.【Results】The disease control rate was 42.5% (17/40) in the Group A, and that of the control group was 47.5%(19/40), there was no significant difference between the two groups (P>0.05); However, the incidence of blood toxicity, diarrhea and Ⅰ~Ⅱperipheral neurotoxicity in patients of the Group B were significantly higher than those in the Group A, and the difference was statistically significant (P<0.05).【Conclusion】If the they can withstand, patients with advanced gastric cancer may use epirubicin, oxaliplatin combined with capecitabine as second-line chemotherapy after the first-line chemotherapy proves to be ineffective. The effect is exact, the side effect is small, and is worthy of clinical treatment.
林燕;段春燕;王巧琳;陈卉;. 表柔比星,奥沙利铂和卡培他滨二线方案治疗晚期胃癌的疗效[J]. 医学临床研究, 2017, 34(4): 696-698,701.
LIN Yan,DUAN Chun-yan, WANG Qiao-lin,et al. Clinical Efficacy and Side effects of Epirubicin, Oxaliplatin and Capecitabine in the Treatment of Advanced Gastric Cancer. JOURNAL OF CLINICAL RESEARCH, 2017, 34(4): 696-698,701.
2017, Vol. 34 
